首页> 美国卫生研究院文献>Diabetes Technology Therapeutics >Letter Written in Response to van Bon et al.: Insulin Glulisine Compared to Insulin Aspart and to Insulin Lispro Administered by Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: A Randomized Controlled Trial

【2h】

Letter Written in Response to van Bon et al.: Insulin Glulisine Compared to Insulin Aspart and to Insulin Lispro Administered by Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: A Randomized Controlled Trial

机译：回应van Bon等人的信：在1型糖尿病患者中通过连续皮下注射胰岛素与门冬胰岛素和赖斯普胰岛素进行比较的谷氨酰胺：随机对照试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 Diabetes Technology Therapeutics
作者
Lois Jovanovič;
展开▼
作者单位

展开▼
年(卷),期 -1(13),8
年度 -1
页码 869–870
总页数 2
原文格式 PDF
正文语种
中图分类基础医学;
关键词

相似文献

外文文献
中文文献
专利

1. Letter written in response to van bon et Al.: "Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial". [J] . Anonymous Diabetes technology & therapeutics . 2011,第8期

机译：为回应van bon等人而写的信：“在1型糖尿病患者中，相比于门冬胰岛素和通过连续皮下注射胰岛素给予赖脯胰岛素的胰岛素，谷胱甘肽：一项随机对照试验”。
2. Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial. [J] . van Bon AC, Bode BW, Sert Langeron C, Diabetes technology & therapeutics . 2011,第6期

机译：在1型糖尿病患者中，通过持续皮下胰岛素输注与门冬胰岛素和赖脯胰岛素相比，谷胱甘肽胰岛素的随机对照试验。
3. INSULIN LISPRO WITH CONTINUOUS SUBCUTANEOUS INSULIN INFUSION IS SAFE AND EFFECTIVE IN PATIENTS WITH TYPE 2 DIABETES: A RANDOMIZED CROSSOVER TRIAL OF INSULIN LISPRO VERSUS INSULIN ASPART [J] . Thrasher James, Bhargava Anuj, Rees Tina M., Endocrine practice: official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists . 2015,第3期

机译：连续皮下注射胰岛素的胰岛素替代品在2型糖尿病患者中是安全有效的：胰岛素替代品与胰岛素ASPART的随机交叉试验
4. Comparing artificial pancreas controlled by hybrid "closed-loop" machine learning (ML) trained algorithm to multi-daily injection (MDI), insulin pump without CGM and "sensor assisted" insulin pump therapies for Diabetes Type 1 (DT1) treatment [C] . Joan Carles Peiró International Conference on Data Analytics for Business and Industry: Way Towards a Sustainable Economy . 2020

机译：将通过混合“闭环”机器学习（ML）控制的人工胰腺培训算法对多日注于多日注射（MDI），胰岛素泵而没有CGM和“传感器辅助”胰岛素泵疗法1型（DT1）处理
5. Evaluating Hypoglycemic Risk of Two Basal Insulin Delivery Methods for Type 1 Diabetes: A Comparison of Tresiba Insulin Against Continuous Subcutaneous Insulin Infusion Using Data from Continuous Glucose Monitors [D] . Lane, Benjamin. 2020

机译：评估1型糖尿病两种基础胰岛素递送方法的低血糖风险：使用来自连续葡萄糖监测器的数据进行TRESIBA胰岛素对连续皮下胰岛素输注的比较
6. Pharmacological properties of faster‐acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized double‐blind crossover trial [O] . Tim Heise, Eric Zijlstra, Leszek Nosek, -1

机译：连续皮下注射胰岛素的1型糖尿病患者速效门冬胰岛素与门冬胰岛素的药理特性：一项随机双盲交叉试验
7. Letter Written in Response to van Bon et al.: “Insulin Glulisine Compared to Insulin Aspart and to Insulin Lispro Administered by Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: A Randomized Controlled Trial” [O] . Jovanovič, Lois 2011

机译：回应van Bon等人的信：“在1型糖尿病患者中通过连续皮下注射胰岛素与门冬胰岛素和赖斯普胰岛素进行比较的谷氨酰胺：随机对照试验”

Letter Written in Response to van Bon et al.: Insulin Glulisine Compared to Insulin Aspart and to Insulin Lispro Administered by Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: A Randomized Controlled Trial

著录项

相似文献

相关主题

期刊订阅